Cash and investments totaled $24.9 million as of March 31, 2026, compared to $28.2 million as of December 31, 2025. The Company believes its current cash and investment resources are sufficient to fund operations into the third quarter of 2027, including advancement of the TAVVE pivotal study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVNO:
- enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study
- enVVeno Medical Wins FDA IDE for TAVVE Trial
- enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year
- enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026
- AI Models Reiterate High-Risk, Speculative View on enVVeno Medical (NVNO)